Clik here to view.
National Heart Research Institute Singapore and Thermo Fisher Scientific...
SINGAPORE Researchers and medical doctors in Singapore will have a new opportunity to participate in the Pluripotent Stem Cell Training Course, a workshop which showcases the latest pluripotent stem...
View ArticleClik here to view.
BioCision Announces Industry’s First Automated Biospecimen Thawing System
SAN RAFAEL, Calif. BioCision, LLC, a leader in advanced products to improve biospecimen and biologics handling and standardization, today announced the availability of ThawSTAR™ automated sample...
View ArticleClik here to view.
Cytori Expects New Japan Laws to Boost Adoption of Cytori Cell Therapy
SAN DIEGO Cytori Therapeutics, Inc. (NASDAQ: CYTX) today confirmed that two Japanese regenerative medicine laws, which went into effect on November 25, 2014, remove regulatory uncertainties and...
View ArticleClik here to view.
糖尿病，利用胰脏细胞做根本性治疗的时代已经到来
首尔, 韩国 (美国商业资讯) — (株)STC LIFE(会长：李桂浩)干细胞治疗研究院(STC Stem cell Treatment & Research Institute / www.stcstri.com)通过数十年的研究成功利用能够分化为所有组织及脏器并无任何副作用的新万能细胞分化出担任胰脏中胰岛素调节机能的β细胞。 STC...
View ArticleClik here to view.
膵臓細胞利用により根本的治療の道が開かれる糖尿病 … STC Life、世界で初めて万能幹細胞から膵臓細胞への分化に成功
韓国・ソウル （ビジネスワイヤ） — STC Life Co., Ltd.（会長：KYE HO LEE）の幹細胞治療研究院（STC Stem cell Treatment & Research...
View ArticleClik here to view.
A New Era Comes When Diabetes Can Be Treated Basically Using Cells of Pancreas
SEOUL, South Korea STC Stem Cell Treatment & Research Institute (www.stcstri.com) of STC Life Co., Ltd. (Chairman: Kye Ho Lee) succeeded in differentiating new pluripotent stem cells without...
View ArticleClik here to view.
FDAがCytoriに強皮症の極めて重要な治験を条件付きで承認
サンディエゴ （ビジネスワイヤ） サイトリ・セラピューティクス（NASDAQ: CYTX）は、本日、アメリカ食品医薬品局（FDA）が、STARという名称の極めて重要な治験について、治験用医療機器の適用免除（IDE）への条件付き承認を行ったことを発表した。治験の目的は、強皮症による手の機能障害の有望な治療法として、Cytori Cell...
View ArticleClik here to view.
Promega PowerPlex® Fusion 6C System Improves Mixture Interpretation with...
MADISON, Wis. Promega Corporation announces the release of the PowerPlex® Fusion 6C System, a 6-color, 27-locus multiplex. The system combines common and informative loci to overcome typical...
View ArticleClik here to view.
法国药管局核准THERAVECTYS按GMP标准生产用于临床的慢病毒载体和CAR-T细胞治疗药物
Smart Multimedia Gallery ビデオタイトル QuickTimeで再生 WindowsMediaで再生 巴黎 (美国商业资讯) —...
View ArticleClik here to view.
テラヴェクティスがGMP規格の下で臨床使用／CAR-T細胞療法向けレンチウイルスベクターを生産するための認可をフランス医薬品当局から取得
Smart Multimedia Gallery ビデオタイトル QuickTimeで再生 WindowsMediaで再生 パリ （ビジネスワイヤ） —...
View ArticleClik here to view.
SanBio Announces Pricing of Initial Public Offering on Tokyo Stock Exchange
TOKYO & MOUNTAIN VIEW, Calif. SanBio, Co. Ltd. announced today the pricing of an initial public offering of 4,000,000 shares, or 8.6 percent of its common stock, at an offer price of 2,000...
View ArticleClik here to view.
4SC Signs Licensing and Development Agreement with Menarini for Resminostat...
SINGAPORE 4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for cancer and autoimmune diseases, and Singapore based Menarini Asia-Pacific...
View ArticleClik here to view.
4SCが日本を除くアジア太平洋地域を対象にレスミノスタットのライセンス／開発契約をメナリーニと締結
シンガポール （ビジネスワイヤ）– がん／自己免疫疾患向けの低分子標的治療薬を創薬・開発している4SC AG（フランクフルト、プライム・スタンダード：VSC）と、シンガポールに拠点を置くメナリーニ・アジアパシフィック・ホールディングス（メナリーニAP）は、日本を除くアジア太平洋地域を対象に4SCの抗がん化合物レスミノスタットのライセンス／開発提携契約を締結したと発表しました。...
View ArticleClik here to view.
BioTime Licenses Beckman Research Institute of City of Hope to Manufacture...
ALAMEDA, Calif. BioTime, Inc. (NYSE MKT: BTX) today announced a nonexclusive License Agreement between BioTime’s subsidiary ES Cell International Pte Ltd (ESI) and Beckman Research Institute of the...
View ArticleClik here to view.
4SC与Menarini签署Resminostat在日本以外的亚太区的许可和开发协议
新加坡 (美国商业资讯)– 德国4SC 公司（法兰克福主板：VSC），一家探索和开发用于癌症和自身免疫疾病的小分子靶向药物的公司，连同总部位于新加坡的Menarini Asia-Pacific Holdings Pte. Ltd. (“美纳里尼亚太”) 宣布，已就4SC的抗癌化合物resminostat在日本以外的亚太 (“APAC”) 区的许可和开发缔结合作关系。...
View ArticleClik here to view.
Successful Closure of the TOB for Cellular Dynamics International Inc., a...
TOKYO On April 3, 2015, FUJIFILM Holdings Corporation (President: Mr. Shigehiro Nakajima) (hereafter, “Fujifilm”) launched a tender offer bid (hereafter, “TOB”) offering USD 16.50 per share for the...
View ArticleClik here to view.
Generon Received US FDA Clearance to Initiate Phase IIa Study With F-652, a...
SHANGHAI Generon Corporation, a leading biotech company in China, today announced that it received US FDA clearance of the IND for a Phase IIa study, entitled “Recombinant Human...
View ArticleClik here to view.
武田宣布Ixazomib维持治疗用于新诊断多发性骨髓瘤的全球3期研究入组首例患者
马萨诸塞州剑桥和日本大阪 (美国商业资讯)–武田药品工业株式会社(TSE: 4502)今天宣布，评估研究中的口服新药ixazomib的3期TOURMALINE-MM4研究已入组首例患者。该项优效性研究旨在展示口服给药的蛋白酶体持续抑制能否改善多发性骨髓瘤患者的远期临床转归。...
View ArticleClik here to view.
BioCision to Develop Customized ThawSTAR Automated Cell Thawing System for...
SAN RAFAEL, Calif. BioCision, LLC, a leader in advanced technology to improve biological sample handling and standardization, today announced that it will collaborate with Celgene Cellular...
View ArticleClik here to view.
Allele Biotechnology & Pharmaceuticals Closes Purchase of cGMP Facility for...
SAN DIEGO Allele Biotechnology & Pharmaceuticals, Inc. (“Allele”), a leader in the development of specialized cells for pharmaceutical drug discovery and regenerative medicine, today announced...
View Article